TP53 and acute myeloid leukemia: Patients with t-AML had a slightly higher frequency of TP53 mutation (9% versus 4%) and lower frequency of CEBPA mutations (5% versus 15%), although these differences were not statistically significant, possibly due to the small numbers of sequenced patients in the t-AML subgroup.